Discovery of potent and orally bioavailable 17β-hydroxysteroid dehydrogenase type 3 inhibitors

Bioorganic and Medicinal Chemistry

Volumn 20, Issue 10, 2012, Pages 3242-3254

  Harada, Koichiro ^a   Kubo, Hideki ^a   Abe, Jun ^a   Haneta, Mari ^a   Conception, Arnel ^b   Inoue, Shinichi ^b   Okada, Satoshi ^b   Nishioka, Kazuhiko ^a  

^a SUMITOMO CHEMICAL CO LTD   (Japan)

^b Sumika Technoservice Corporation   (Japan)

Author keywords

17 HSD3 inhibitors; 17 Hydroxysteroid dehydrogenase type 3 (17 HSD3); Oxazolidinedione; Phosphate ester prodrug; Prostate cancer; Thiazolidinedione

Indexed keywords

17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 3; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 (1,3 BENZODIOXOL 5 YL) 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 2 THIOXO 1,3 OXAZOLIDIN 4 ONE; 3 ALLYL 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 2 THIOXO 1,3 THIAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 2 THIOXO 1,3 THIAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 (1 METHYLPIPERIDIN 4 YL) 2 THIOXO 1,3 THIAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 (2 METHOXYPHENYL) 2 THIOXO 1,3 OXAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 (3 METHOXYPHENYL) 2 THIOXO 1,3 OXAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 (4 CHLOROPHENYL) 2 THIOXO 1,3 OXAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 (4 CYANOPHENYL) 2 THIOXO 1,3 OXAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 (4 FLUOROPHENYL) 2 THIOXO 1,3 OXAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 (4 METHOXYBENZYL) 2 THIOXO 1,3 THIAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 (4 METHOXYCARBONYLPHENYL) 1,3 OXAZOLIDIN 2,4 DIONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 (4 METHOXYPHENYL) 1,3 OXAZOLIDIN 2,4 DIONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 (4 METHOXYPHENYL) 2 THIOXO 1,3 OXAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 (4 METHOXYPHENYL) 2 THIOXO 1,3 THIAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 (4 METHYLPHENYL) 2 THIOXO 1,3 OXAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 (4 TRIFLUOROMETHYLPHENYL) 2 THIOXO 1,3 OXAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 (METHOXYETHYL) 2 THIOXO 1,3 THIAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 (TETRAHYDROPYRAN 4 YL) 2 THIOXO 1,3 THIAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 CYCLOHEXYL 2 THIOXO 1,3 THIAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 METHYL 2 THIOXO 1,3 THIAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 PHENYL 2 THIOXO 1,3 OXAZOLIDIN 4 ONE; 5 (3 BROMO 4 HYDROXYBENZYLIDENE) 3 PROPAGYL 2 THIOXO 1,3 THIAZOLIDIN 4 ONE; 5 [3,5 DICHLORO 4 (PHOSPHONOXY)BENZYLIDENE] 3 (4 METHOXYPHENYL) 2 THIOXO 1,3 OXAZOLIDIN 4 ONE; GONADORELIN; OXAZOLIDINEDIONE DERIVATIVE; TESTOSTERONE; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG MEGADOSE; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; TESTOSTERONE SYNTHESIS;

17-HYDROXYSTEROID DEHYDROGENASES; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; ENZYME INHIBITORS; ESTERS; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; PHOSPHATES; PROSTATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TESTOSTERONE;

EID: 84860430801     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2012.03.052     Document Type: Article

References (23)

1. C. Jeanne, and R. Carmen Cancer Facts Figures 2009
2. A. van Bokhoven, M. Varella-Garcia, C. Korch, W.U. Johannes, E.E. Smith, H.L. Miller, S.K. Nordeen, G.J. Miller, and M.S. Lucia Prostate 57 2003 205
3. D. Poirier Curr. Med. Chem. 10 2003 453
4. J. Adamski, and F. Jakob J. Mol. Cell. Endocrinol. 171 2001 1
5. V. Luu-The, I. Dufort, G. Pelletier, and F. Labrie Mol. Cell. Endocrinol. 171 2001 77
6. E. Koh, T. Noda, and M. Namiki Prostate 53 2002 154
7. Guzi, T. J.; Liu, Yi-Tsung; Doll, R. J.; Saksena, A.; Girijavallabhan, V. M.; Pachter, J. A. U.S. Patent 20040138226, 2004.
8. R. Maltais, V. Luu-The, and D. Poirier J. Med. Chem. 45 2002 640
9. B.E. Fink, A.V. Gavai, J.S. Tokarski, B. Goyal, R. Misra, H.Y. Xiao, S.D. Kimball, W.C. Han, D. Norris, T.E. Spires, D. You, M.M. Gottardis, M.V. Lorenzi, and G.D. Vite Bioorg. Med. Chem. Lett. 16 2006 1532
10. N. Vicker, C.M. Sharland, W.B. Heaton, A.M.R. Gonzalez, H.V. Bailey, A. Smith, J.S. Springall, J.M. Day, H.J. Tutill, M.J. Reed, A. Purohit, and B.V.L. Potter Mol. Cell. Endocrinol. 301 2009 259
11. K. Harada, H. Kubo, A. Tanaka, and N. Kazuhiko Bioorg. Med. Chem. Lett. 22 2012 504
12. M. Radi, L. Botta, G. Casaluce, M. Bernardini, and M. Botta J. Comb. Chem. 12 2010 200
13. B. Holmberg J. Prakt. Chem. 81 1910 451
14. G. Jones Org. React. 15 1967 204
15. P. Fresneau, M. Cussac, J.M. Morand, B. Szymonski, D. Tranqui, and G. Leclerc J. Med. Chem. 41 1998 4706
16. E. Fukushi, and J. Kawabata Magn. Reson. Chem. 44 2006 475
17. H. Finkbeiner J. Org. Chem. 30 1965 3414
18. L.J. Silverberg, J.L. Dillon, and P. Vemishetti Tetrahedron Lett. 37 1969 771
19. C.E. Mckenna, and J. Schmidhauser J. Chem. Soc., Chem. Commun. 1 1979 739
20. E. Breuer, M. Safadi, M. Chorev, and D. Gibson J. Org. Chem. 55 1990 6147
21. S. Lazar, and G. Guillaumet Synth. Commun. 22 1992 923
22. Y. Ideyama, M. Kudoh, K. Tanimoto, Y. Susaki, T. Nanya, T. Nakahara, H. Ishikawa, T. Yoden, M. Okada, T. Fujikura, H. Akaza, and H. Shikama Prostate 37 1998 10
23. R. Jarkko, K. Hanna, H. Tycho, O. Reza, O. Dooman, J. Tomi, and S. Junko Nat. Rev. Drug Disc. 7 2008 255